MET and small cell lung carcinoma: Besides the classical EGFR-T790M mutation and transformation to a small-cell lung cancer (SCLC) phenotype, aberrant activations of bypass signaling pathways responsible for EGFR TKI resistance have been identified, such as c-MET amplification and abnormal activation of the PI3K/AKT pathway 4.